Elevated serum IL-10/IL-6 ratio as a novel biomarker for secondary central nervous system lymphoma and poor prognosis in DLBCL.

Front Immunol · 2025 · PMC12380870 · PMID 40881684

Europe PMC DOI

hedged sentence

0.2890

closest p · 5.8× alpha

0.2890

boldest claim

The sentences

did not reach statistical significancep =0.289not close (p > 0.1)

Although the survival difference did not reach statistical significance (χ2=1.124, p =0.289), patients with ratios <1.0 demonstrated a numerically longer mean OS (11.42 years, 95% CI: 9.66–13.19) than those with ratios ≥1.0 (5.78 years, 95% CI: 4.94–6.63), suggesting a potential prognostic trend. 3.5.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.